

CURRICULUM VITAE

Dr. Ciro P. Romano, MD, PhD

Education & Professional Experiences:

2002-present

Assistant Professor of Internal Medicine, "Luigi Vanvitelli"
University of Campania School of Medicine, Naples, Italy

2001

Postgraduate Specialty Degree in Allergy and Clinical
Immunology, Second University of Naples School of Medicine,
Naples, Italy

2000-2001

Resident, Postgraduate School of Allergy and Clinical
Immunology, Second University of Naples School of Medicine,
Naples, Italy

1999

Postdoctoral fellow, Konishi-MUSC Institute for Inflammation
Research, Medical University of South Carolina, Charleston, SC,
USA

1997-1998

Postdoctoral fellow, Laboratory of Tumor Immunology and
Experimental Immunotherapy, Hollings Cancer Center, Medical
University of South Carolina, Charleston, SC, USA

1997

Resident, Postgraduate School of Allergy and Clinical
Immunology, Second University of Naples School of Medicine,
Naples, Italy

1997

Ph.D., Second University of Naples School of Medicine, Naples,
Italy

1995-1996

Visiting Research Fellow, Laboratory of Tumor Immunology and
Experimental Immunotherapy, Hollings Cancer Center, Medical
University of South Carolina, Charleston, SC, USA

1992-1995

Clinical Assistant, Division of Internal Medicine, “F. Magrassi”
Department of Clinical and Experimental Medicine, Second
University of Naples School of Medicine, Naples, Italy

1992
M.D., “Federico II” University School of Medicine, Naples, Italy

Qualification : M.D., Ph.D.
Specialist in Allergy and Clinical Immunology
Specialist in Internal Medicine

Awards and Honors:

2001
Annual Award from the Accademia di Scienze Mediche e Chirurgiche della Società Nazionale di Scienze, Lettere e Arti in Napoli, via Mezzocannone 8, 80138 Naples, Italy

Membership of Scientific or Professional Societies:

1992-present
Italian Society of Internal Medicine (SIMI)

List of Publications:

- 1) De Bellis A, Bizzarro A, Gattoni A, **Romano C**, Di Martino S, Sinisi AA, Abbadessa S, Bellastella A. *Behavior of sICAM-1 and sELAM-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.* J Clin Endocrinol Metab 1995;80:2118-2121
- 2) Gattoni A, **Romano C**, Cecere A, Caiazzo R, Grima P, Altucci P. *Efficacy of human leukocyte interferon- α treatment in elderly patients with hepatitis C virus-related chronic liver disease.* Arch Gerontol Geriatr 1996; (Suppl 5):305-312
- 3) Gattoni A, Cecere A, **Romano C**, Di Martino P, Caiazzo R, Rippa A. *Case report of a monoclonal gammopathy in a patient with chronic hepatitis: effects of β -interferon treatment.* Panminerva Med 1996;38:175-178
- 4) Gattoni A, **Romano C**, Cecere A, Caiazzo R. *Eosinophilia triggered by β -interferon therapy for chronic hepatitis C.* Eur J Gastroenterol Hepatol 1997;9:909-911
- 5) Gattoni A, **Romano C**, Cecere A, De Bellis A, Caiazzo R, Bizzarro A. *Serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) as a potential marker of disease activity and remission in patients with chronic hepatitis C.* Panminerva Med 1997;39:256-262
- 6) **Romano C**, Cecere A, Caiazzo R, Gattoni A. *T cell immunity in hepatitis C virus infection.* Hepatology Res 1998;12:151-157

- 7) Cecere A, **Romano C**, Caiazzo R, Lucariello A, Tancredi L, Gattoni A. *Lymphoblastoid α-IFN, leukocytic α-IFN and natural β-IFN in the treatment of chronic hepatitis C: a clinical comparison of 150 cases.* Hepatology Res 1999;15:225-237
- 8) De Vita F, Orditura M, Galizia G, **Romano C**, Infusino S, Auriemma A, Lieto E, Catalano G. *Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies.* Cancer 1999;86:1936-43
- 9) De Vita F, Orditura M, Galizia G, **Romano C**, Roscigno A, Lieto E, Catalano G. *Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.* Chest 2000;117:365-373
- 10) De Vita F, Orditura M, Galizia G, **Romano C**, Lieto E, Iodice P, Tuccillo C, Catalano G. *Serum interleukin-10 is an independent prognostic factor in advanced solid tumors.* Oncol Rep 2000;7:357-361
- 11) Newton DA, **Romano C**, Gattoni-Celli S. *Semiallogeneic cell hybrids as therapeutic vaccines for cancer.* J Immunother 2000;23:246-254
- 12) Orditura M, **Romano C**, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G, Catalano G. *Behaviour of interleukin-2 serum levels in advanced non small cell lung cancer patients: relationship with response to therapy and survival.* Cancer Immunol Immunother 2000;49:530-536
- 13) De Vita F, **Romano C**, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G. *Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator.* J Interferon Cytokine Res 2001;21:45-52
- 14) Astarita C, Gargano D, **Romano C**, Cutajar M, Manguso F, Montanaro D, Napolitano A, Pezzuto F, Lo Schiavo M, Altucci P, Abbate G. *Long-term absence of sensitization to mepivacaine as assessed by a diagnostic protocol including patch testing.* Clin Exp Allergy 2001;31:1762-1770
- 15) Astarita C, Gargano D, Manguso F, **Romano C**, Montanaro D, Pezzuto F, Bonini S, Altucci P, Abbate G. *Epidemiology of allergic occupational diseases induced by *Tetranychus urticae* in greenhouse and open field farmers living in a temperate climate area.* Allergy 2001;56:1157-1163
- 16) Cecere A, Ciaramella F, Tancredi L, **Romano C**, Gattoni A. *Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis. Results of a randomised trial.* Clin Drug Invest 2002;22(Suppl 1):7-14
- 17) Galizia G, Orditura M, **Romano C**, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F. *Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery.* Clin Immunol 2002;102:169-178
- 18) Gargano D, **Romano C**, Manguso F, Cutajar M, Altucci P, Astarita C. *Relationship between total and allergen-specific IgE serum levels and presence of symptoms in farm workers sensitized to *Tetranycus Urticae*.* Allergy 2002;57:1044-1047
- 19) De Fanis U, Dalla Mora L, **Romano C**, Sellitto A, Tirelli A, Lucivero G. *Altered constitutive and activation-induced expression of CD95 by B- and T-cells in B-CLL.* Haematologica 2002;87:325-327

- 20) Galizia G, Lieto E, Ferraraccio F, Castellano P, De Vita F, Orditura M, **Romano C**, Pignatelli C. *A true splenic cyst producing carbohydrate antigen 19-9 and cancer antigens 50 and 125, but not interleukin 10.* Dig Surg 2003;20:71-74
- 21) De Fanis U, **Romano C**, Dalla Mora L, Sellitto A, Guastafierro S, Tirelli A, Bresciano E, Giunta R, Lucivero G. *Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.* Oncol Rep 2003;10:653-658
- 22) Marfella R, Siniscalchi M, Esposito K, Sellitto A, De Fanis U, **Romano C**, Portoghesi M, Siciliano S, Nappo F, Sasso FC, Mininni N, Cacciapuoti F, Lucivero G, Giunta R, Verza M, Giugliano D. *Effects of stress hyperglycemia on acute myocardial infarction. Role of inflammatory process in functional cardiac outcome.* Diab Care 2003;26:3129-3135
- 23) **Romano C**, De Fanis U, Sellitto A, Dalla Mora L, Chiurazzi F, Giunta R, Rotoli B, Lucivero G. *Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.* Leuk Lymphoma 2003;44:1963-1971
- 24) De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, **Romano C**, Ciardiello F, Catalano G, Pignatelli C, Galizia G. *Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.* Cancer 2004;100:270-278
- 25) Giunta R, Cravero RG, Granata G, Sellitto A, **Romano C**, De Fanis U, Foccillo G, De Capite C, Santini M, Rossiello L, Rossiello R, Lucivero G. *Primary cardiac T cell lymphoma.* Ann Hematol 2004;83:450-454
- 26) Galizia G, Lieto E, Ferraraccio F, Orditura M, De Vita F, Castellano P, Imperatore V, **Romano C**, Ciardiello F, Agostini B, Pignatelli C. *Determination of molecular marker expression can predict clinical outcome in colon carcinomas.* Clin Cancer Res 2004;10:3490-3499
- 27) Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, **Romano C**, Vollaro M, Agostini B, Pignatelli C, De Vita F. *Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery.* Dis Colon Rectum 2004;47:1904-1914
- 28) **Romano C**, De Fanis U, Sellitto A, Chiurazzi F, Guastafierro S, Giunta R, Tirelli A, Rotoli B, Lucivero G. *Induction of CD95 upregulation does not render chronic lymphocytic leukemia B cells susceptible to CD95-mediated apoptosis.* Immunol Lett 2005;97:131-139
- 29) Minervini F, Fornelli F, Lucivero G, **Romano C**, Visconti A. *T-2 toxin immunotoxicity on human B and T lymphoid cell lines.* Toxicology 2005;210:81-91
- 30) **Romano C**, Sellitto A, De Fanis U, Rossiello R, Rossiello L, Giunta R, Lucivero G. *A scleroderma-like cutaneous syndrome associated with a marked Th₂-type immune response occurring after a prosthetic joint implant.* J Clin Rheumatol 2009;15:133-137
- 31) **Romano C**, Sellitto A, De Fanis U, Esposito G, Arbo P, Giunta R, Lucivero G. *Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria.* Ann Allergy Asthma Immunol 2010;104:95-97
- 32) Sellitto A, **Romano C**, Giunta R, Galizia G, Lucivero G. *A subtle case of iron-deficiency anemia.* Intern Emerg Med 2011;6:191-192

- 33) Sellitto A, Galizia G, De Fanis U, Lieto E, Zamboli A, Orditura M, De Vita F, Giunta R, Lucivero G, **Romano C**. *Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery.* J Clin Immunol 2011;31:1095-1104
- 34) Lucivero G, **Romano C**, Ferraraccio F, Sellitto A, De Fanis U, Giunta R, Guarino A, Auriemma PP, Benincasa M, Iovino F. *Lupus mastitis in systemic lupus erythematosus: a rare condition requiring a minimally invasive diagnostic approach.* Int J Immunopathol Pharmacol 2011;24:1125-1129
- 35) Sellitto A, Santoriello A, De Fanis U, Benevento R, Perna G, Rossiello R, De Maio M, Giunta R, Canonico S, Lucivero G, **Romano C**. *Granulomatous lobular mastitis: another manifestation of systemic lupus erythematosus?* Breast J 2013;19:331-332
- 36) Galizia G, Gemei M, Orditura M, **Romano C**, Zamboli A, Castellano P, Mabilia A, Auricchio A, De Vita F, Del Vecchio L, Lieto E. *Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients.* J Gastrointest Surg 2013;17:1809-1818
- 37) Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, **Romano C**, Adinolfi LE. *Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.* World J Hepatol 2013;5:528-540
- 38) **Romano C**, Sellitto A, Restivo L, Adinolfi LE. *Clinically-irrelevant positivity for serum proteinase 3-ANCA in HIV disease.* Int J Immunopathol Pharmacol 2013;26:957-959
- 39) Lieto E, Galizia G, Orditura M, **Romano C**, Zamboli A, Castellano P, Mabilia A, Auricchio A, De Vita F, Gemei M. *CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence.* Oncol Lett 2015;9:542-550
- 40) Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, **Romano C**, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A. *Chronic HCV infection and neurological and psychiatric disorders: an overview.* World J Gastroenterol 2015;21:2269-2280
- 41) **Romano C**, Sellitto A, Chiurazzi F, Simeone L, De Fanis U, Raia M, Del Vecchio L, Lucivero G. *Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.* Int J Hematol 2015;101:67-74
- 42) **Romano C**, Sellitto A, De Fanis U, Balestrieri A, Savoia A, Abbadessa S, Astarita C, Lucivero G. *Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.* Clin Drug Investig 2015;35:159-168
- 43) Galizia G, Lieto E, Zamboli A, De Vita F, Castellano P, **Romano C**, Auricchio A, Cardella F, De Stefano L, Orditura M. *Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers. A propensity score-matched analysis.* Surgery 2015;158:112-120
- 44) **Romano C**. *Omalizumab therapy for children and adolescents with severe allergic asthma.* Expert Rev Clin Immunol 2015;11:1309-1319
- 45) Sellitto A, De Fanis U, Balestrieri A, Savoia A, Astarita C, **Romano C**. *Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with*

chronic spontaneous urticaria: a preliminary report. Eur Ann Allergy Clin Immunol 2017;49:171-175

- 46) Adinolfi LE, Nevola R, Rinaldi L, **Romano C**, Giordano M. *Chronic hepatitis C virus infection and depression.* Clin Liver Dis 2017;21:517-534
- 47) **Romano C**, Sirotti V, Farinaro V, Luiso V, Solaro E, De Sio C, Salemme A, Del Mastro A, Giunta R. *Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: a brief case-based review.* Eur J Rheumatol 2017;4:231-233
- 48) Lieto E, Galizia G, Auricchio A, Cardella F, Mabilia A, Basile N, Del Sorbo G, Castellano P, **Romano C**, Orditura M, Napolitano V. *Preoperative neutrophil to lymphocyte ratio and lymphocyte to monocyte ratio are prognostic factors in gastric cancers undergoing surgery.* J Gastrointest Surg 2017;21:1764-1774
- 49) **Romano C**, Del Mastro A, Sellitto A, Solaro E, Esposito S, Cuomo G. *Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.* Clin Rheumatol 2018;37:1695-1700
- 50) Sellitto A, Adinolfi LE, **Romano C***, Iovino F, Auriemma PP, Russo D, De Vita F. *Plantar Kaposi sarcoma revealed by antisynthetase syndrome.* J Clin Rheumatol 2018;24:281-285
- 51) **Romano C**, Cuomo G, Ferrara R, Del Mastro A, Esposito S, Sellitto A, Adinolfi LE. *Uncommon immune-mediated extrahepatic manifestations of HCV infection.* Expert Rev Clin Immunol 2018;14:1089-1099
- 52) **Romano C**, Pace G, Sellitto A, Reginelli A. *Omalizumab as a last resort therapy for intractable, severe chronic allergic rhinosinusitis.* Allergo J Int 2019;28:99-102
- 53) **Romano C**, Esposito S, Ferrara R, Cuomo G. *Choosing the most appropriate biologic therapy for Crohn's disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions.* Expert Opin Biol Ther 2020;20:49-62
- 54) **Romano C**. *Safety and effectiveness of dupilumab in prurigo nodularis.* J Investig Allergol Clin Immunol 2021;31:162-163
- 55) **Romano C**, Esposito S, Ferrara R, Cuomo G. *Tailoring biologic therapy for real-world rheumatoid arthritis patients.* Expert Opin Biol Ther 2021;21:661-674
- 56) Serban T, Allara R, Azzolini V, Bellintani C, Belloli L, Belai Beyene N, Bucci R, Caporali R, Cappelli A, Corbelli V, DE Gennaro F, Fusaro E, Giusti A, Govoni M, Magnani L, Manzo C, **Romano C**, Rossini M, Santilli D, Saviola G, Sinigaglia L, Bianchi G; MARTE study group. *Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study.* Minerva Med 2021;112:246-254
- 57) Nevola R, Rinaldi L, Zeni L, **Romano C**, Marrone A, Galiero R, Pafundi PC, Acierno C, Vetrano E, Adinolfi LE. *Changes in clinical scenarios, management and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals.* Expert Rev Gastroenterol Hepatol 2021;15:643-656
- 58) Masini F, Galiero R, Pafundi PP, Gjeloshi K, Pinotti E, Ferrara R, **Romano C**, Adinolfi LE, Sasso FC, Cuomo G. *Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients.* J Scleroderma Relat Disord 2021, *in press*
- 59) **Romano C**, Esposito S, Donnarumma G, Marrone A. *Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common*

variable immunodeficiency after immunization with messenger RNA vaccines. Ann Allergy Asthma Immunol 2021, *in press*

- 60) Marfella R, D'Onofrio N, Sardu C, Scisciola L, Maggi P, Coppola N, **Romano C**, Messina V, Turriziani F, Siniscalchi M, Maniscalco M, Boccalatte M, Napolitano G, Salemme L, Marfella LV, Basile E, Montemurro MV, Papa C, Frascaria F, Papa A, Russo F, Tirino V, Papaccio G, Galdiero M, Sasso FC, Barbieri M, Rizzo MR, Balestrieri ML, Angelillo IF, Napoli C, Paolisso G. *Does poor glycemic control affect the immunogenicity of COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study.* Diabetes Obes Metab 2021, *in press*